Literature DB >> 21826677

In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.

Jiang Ping Luo1, Sarvesh C Vashishtha, Edward M Hawes, Gordon McKay, Kamal K Midha, Jim Fang.   

Abstract

In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide. These studies included use of cDNA-expressed enzymes, correlation analysis with 12 phenotyped human liver microsomal samples, and use of selective inhibitors of cytochrome P450s. The resultant data indicated that loxapine was mainly metabolized by human liver microsomes to (i) 8-hydroxyloxapine by CYP1A2, (ii) 7-hydroxyloxapine by CYP2D6, (iii) N-desmethyloxapine by CYP3A4 and (iv) loxapine N-oxide by CYP3A4. The involvement of flavin-containing monooxygenase (FMO) in the formation of loxapine N-oxide was also observed.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826677     DOI: 10.1002/bdd.768

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  6 in total

1.  Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery.

Authors:  Yin Cheong Wong; Shuai Qian; Zhong Zuo
Journal:  Pharm Res       Date:  2014-02-20       Impact factor: 4.200

2.  CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.

Authors:  Zhexue Wu; Doohyun Lee; Jeongmin Joo; Jung-Hoon Shin; Wonku Kang; Sangtaek Oh; Do Yup Lee; Su-Jun Lee; Sung Su Yea; Hye Suk Lee; Taeho Lee; Kwang-Hyeon Liu
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 3.  Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

4.  Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents.

Authors:  Min Dong; Tsuyoshi Fukuda; Sally Selim; Mark A Smith; Laura Rabinovich-Guilatt; James V Cassella; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2017-10       Impact factor: 6.447

Review 5.  Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.

Authors:  Diane Merino; Arnaud Fernandez; Alexandre O Gérard; Nouha Ben Othman; Fanny Rocher; Florence Askenazy; Céline Verstuyft; Milou-Daniel Drici; Susanne Thümmler
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

6.  Effect of smoking on the pharmacokinetics of inhaled loxapine.

Authors:  Lori H Takahashi; Keith Huie; Daniel A Spyker; Robert S Fishman; James V Cassella
Journal:  Ther Drug Monit       Date:  2014-10       Impact factor: 3.681

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.